Chuikyo Approves Coverage for Chugai’s FoundationOne as Companion Diagnostic for Lynparza

The Central Social Insurance Medical Council, better known as Chuikyo, approved on December 13 insurance coverage for the use of Chugai Pharmaceutical’s comprehensive genomic profiling test FoundationOne CDx Cancer Genome Profile as a companion diagnostic for the PARP inhibitor Lynparza...read more